Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer.

ABSTRACT:

Background

KN026 is a novel bispecific HER2-targeting antibody for HER2-positive recurrent or metastatic breast cancer that showed prolonged median PFS and lessened distinction of PFS regarding the HR subgroup in our phase II clinical trial, compared with PUFFIN study of first-line trastuzumab combined with pertuzumab therapy. A more detailed discovery of its peculiarity is needed for optimal application of KN026 treatment.

Methods

We performed whole-transcriptome sequencing of digital spatial profiling (DSP) on 8 pre/post-treatment tumor samples. Mechanistic explorations were conducted by plasmid transfection, co-culture, CCK8 proliferation assay and flow cytometry.

Results

Compared to the tumor regions with non-objective response (OR), those with OR had high express

SUBMITTER: Ma J 

PROVIDER: S-EPMC12858834 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature